MedTrace Logo

Rebif New Formulation (RNF) Quality of Life (QOL) Study

NCT00472797 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2013-08-07

Study results available
· View outcomes & findings →

Summary

To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).

Conditions

Interventions

DRUG

Rebif New Formulation Non Titrated

human interferon beta 1a - Rebif New Formulation

DRUG

Rebif New Formulation Titrated

Human interferon beta 1a Rebif New Formulation

Sponsors & Collaborators

Principal Investigators

  • Fernando Dangond, MD · EMD Serono

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-02-28
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00472797 on ClinicalTrials.gov